Refine by
Industries served
- Medical / Health Care
- Chemical & Pharmaceuticals
- Mining
- Aerospace & Air Transport
- Oil, Gas & Refineries
- Water and Wastewater
- Monitoring and Testing
- Environmental
- Health and Safety
- Air and Climate
- University / Academia / Research
- Government
- Manufacturing, Other
- Food and Beverage
- Energy
- Construction & Construction Materials
Myeloid Leukemia Suppliers Serving Usa Texas
23 companies found
based inDaxing District, CHINA
Beijing Challen Biotechnology Co., Ltd. (Challenbio) is a leading Chinese flow cytometer manufacturer, located in Biomedical Base of Daxing District, Beijing. It is a high- technology company specializing in R&D, production and sales of biomedical ...
Our product production process strictly follows relevant standards and undergoes multiple rigorous tests to ensure product quality. We pay great attention to details and use a rigorous attitude to ensure the smooth progress of your experiment or ...
based inBoston, MASSACHUSETTS (USA)
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO™s strategy is to focus its resources toward development and commercialization of its product candidates in ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
APVO436 is an optimized ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity, and CD123, a cell surface receptor highly expressed in several ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
based inAustin, TEXAS (USA)
Asuragen a Bio-Techne brand is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using ...
Assessing complete molecular response requires the highest possible assay sensitivity. The FDA-cleared QuantideX® qPCR BCR-ABL IS Kit takes chronic myeloid leukemia (CML) monitoring to a new level of sensitivity ...
based inWoodcliff Lake, NEW JERSEY (USA)
Eagle is a specialty pharmaceutical company working to advance safe and efficient injectable treatments for patients across oncology, critical care, and orphan diseases. At Eagle, we are committed to developing innovative drugs that result in ...
Indications: BENDEKA® is indicated for the treatment of patients with Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established. Indolent B-cell non-Hodgkin lymphoma (NHL) that ...
based inWoodland Hills, CALIFORNIA (USA)
EntroGen offers end-to-end molecular diagnostic solutions by providing hardware, reagents and software. Starting from automated nucleic acid extraction and culminating in genomic interpretation with proprietary software embedded for key decision ...
Mutations in IDH1/2 can lead to the development and/or progression of various types of cancer including secondary glioblastomas and acute myeloid leukemias (AML). IDH1/2 mutations are linked to abnormal histone and ...
based inPearland, TEXAS (USA)
Base Pair Biotechnologies, Inc. is a world-leading provider of highly customized aptamer discovery and development services. The company was founded in 2012. It is privately held and located in the Houston, Texas metropolitan area, close to major ...
Aptamer discovery is a complex process. Customized libraries and selection techniques are employed to achieve selective binding to a target of interest under anticipated conditions. In some cases, selected aptamers may not quite achieve the ...
based inSeocho-gu, SOUTH KOREA
Taking the first step in 1945, JW Group has found the market for domestic therapeutic drug based on its philosophy of respecting life and pioneering spirit. We are strengthening our global market competitiveness by developing leading health care ...
Active Ingredients: cyclophosphamide 50mg per 1 ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
NK cells play a major role in the anti-tumor efficacy of certain tumor-antigen targeting antibodies. NK cells express CD16, an activating receptor that binds to the Fc portion of IgG antibodies. Once activated through CD16, NK cells are able to ...
based inCambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
VOR33 is our lead eHSC product candidate designed to replace the standard of care in transplant settings. Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg or VCAR33, with limited ...
based inSan Diego, CALIFORNIA (USA)
At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer. The genomics revolution is transforming how we treat cancer. We now understand that a patient’s response to treatment depends in part on ...
Kura Oncology’s clinical trial programs represent the next step toward our goal of realizing the full potential of precision medicine. Our investigational trials are studying innovative therapeutic candidates with the potential to help ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
Pursuing an Unmet Need in the Treatment of AML - SENTI-202 is designed to target and eliminate acute myeloid leukemia cells while sparing healthy bone marrow. Our vision is a potential medicine that does not rely on ...
based inNew York, NEW YORK (USA)
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build ...
CD123 is expressed on multiple malignancies including BPDCN, AML, certain myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), B-cell acute lymphoid ...
based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals is developing breakthrough therapies for the treatment of blood diseases. Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx ...
Originally developed for in-house testing, the company’s Advanced peripheral blood Hematopoietic Chimera (“ApbHC”) is a novel type of humanised mouse that presents several advantages over existing mouse models. It has applications ...
based inMont-Saint-Guibert, BELGIUM
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell ...
The manufacturing facility has been instrumental over the past few years in implementing multiple chemistry, manufacturing, and control (CMC) amendments associated with our CAR T programs, including our proprietary OptimAb manufacturing process for ...
based inNew Haven, CONNECTICUT (USA)
Precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. Our goal is to assist oncologists in providing the best care for their patients. At the intersection of academia, cancer ...
Precipio’s HemeScreen acute myeloid leukemia AML Panel offerings are in vitro diagnostic assays that screen for clinically actionable somatic mutations in targets of interest related to AML. This Research Use ...
based inAbbiategrasso, ITALY
Since 1987, Clonit has been focused in developing, manufacturing and distributing of innovative and reliable in Vitro Diagnostic Equipment and Reagents for Molecular Diagnostics. A deep expertise in Molecular Biology mixed to our strong culture of ...
The PML-RARA t(15;17)(q22;q21) is an in vitro diagnostic test for the detection and identification of the PML-RARA gene fusions resulting from the t(15;17)(q22;q21) , by multiplex one-step Real-Time PCR. The PML-RARA t(15;17)(q22;q21) allows also ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
Humans are highly organized systems comprised of approximately 3.72×1013 cells of various types, which maintain proper organ function and normal cellular homeostasis. Despite significant and revolutionary discoveries in the field of cell biology, ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia ...